Keiji Nishibeppu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keiji Nishibeppu has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Shiozaki
Department of Surgery, Division of Digestive Surgery, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
6 shared publications - Hirotaka Konishi
Division of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto Japan
5 shared publications - Shuhei Komatsu
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
5 shared publications - Hitoshi Fujiwara
Kyoto Prefectural University of Medicine
4 shared publications - Toshiyuki Kosuga
Division of Digestive Surgery, Department of Surgery, Yujin-Yamazaki Hospital, Hikone, Shiga, Japan
4 shared publications Atsushi Shiozaki
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
3 shared publications
Latest Publications
- Open Access
A Totally Laparoscopic Transhiatal Approach for Esophageal Cancer During Mediastinoscopic Esophagectomy
Background: Mediastinoscopic esophagectomy is a minimally invasive approach that avoids thoracotomy and single-lung ventilation. We previously performed this procedure using hand-assisted laparoscopic surgery (HALS) and recently established a totally laparoscopic transhiatal approach. This retrospective, non-randomized study reported laparoscopic technique and compared the feasibility and surgical outcomes of these approaches. Methods: We retrospectively reviewed 262 patients who underwent radical mediastinoscopic esophagectomy using left cervical and transhiatal approaches at the Kyoto Prefectural University of Medicine between January 2020 and June 2026. HALS was performed in 202 patients and laparoscopy in 60 patients. Surgical procedures and perioperative outcomes were compared between the groups. Results: Blood loss and total operative time did not differ significantly between the groups, although the transhiatal procedure tended to require a longer operative time with laparoscopy (p = 0.09). The approach used for middle mediastinal lymphadenectomy was similar between the two groups (43% vs. 35%, p = 0.28), and the overall number of dissected lymph nodes, excluding the upper mediastinal and cervical nodes, was comparable. However, significantly more abdominal lymph nodes were dissected with laparoscopy than with HALS (17.9 vs. 15.7, p = 0.04). Laparoscopic gastric mobilization and lymph node dissection were safely performed, with no significant differences in the rate of postoperative complications or curability. Conclusions: The totally laparoscopic transhiatal technique is a feasible and safe approach for mediastinoscopic esophagectomy, with surgical outcomes comparable to those of HALS and not inferior abdominal lymph node dissection. It may be particularly advantageous for cases requiring meticulous abdominal lymphadenectomy.
Open AccessA Totally Laparoscopic Transhiatal Approach for Esophageal Cancer During Mediastinoscopic Esophagectomy
Background: Mediastinoscopic esophagectomy is a minimally invasive approach that avoids thoracotomy and single-lung ventilation. We previously performed this procedure using hand-assisted laparoscopic surgery (HALS) and recently established a totally laparoscopic transhiatal approach. This retrospective, non-randomized study reported laparoscopic technique and compared the feasibility and surgical outcomes of these approaches. Methods: We retrospectively reviewed 262 patients who underwent radical mediastinoscopic esophagectomy using left cervical and transhiatal approaches at the Kyoto Prefectural University of Medicine between January 2020 and June 2026. HALS was performed in 202 patients and laparoscopy in 60 patients. Surgical procedures and perioperative outcomes were compared between the groups. Results: Blood loss and total operative time did not differ significantly between the groups, although the transhiatal procedure tended to require a longer operative time with laparoscopy (p = 0.09). The approach used for middle mediastinal lymphadenectomy was similar between the two groups (43% vs. 35%, p = 0.28), and the overall number of dissected lymph nodes, excluding the upper mediastinal and cervical nodes, was comparable. However, significantly more abdominal lymph nodes were dissected with laparoscopy than with HALS (17.9 vs. 15.7, p = 0.04). Laparoscopic gastric mobilization and lymph node dissection were safely performed, with no significant differences in the rate of postoperative complications or curability. Conclusions: The totally laparoscopic transhiatal technique is a feasible and safe approach for mediastinoscopic esophagectomy, with surgical outcomes comparable to those of HALS and not inferior abdominal lymph node dissection. It may be particularly advantageous for cases requiring meticulous abdominal lymphadenectomy.
- 22 September 2026
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 30 (12)
Prognostic impact of the advanced lung cancer inflammation index in patients aged ≥80 years undergoing gastrectomy for gastric cancer
- 22 September 2026
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 30 (12)
Prognostic impact of the advanced lung cancer inflammation index in patients aged ≥80 years undergoing gastrectomy for gastric cancer
- 26 July 2026
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 19 (5) , 1126-1132
Multimodal approach enables R0 resection in advanced gastric adenocarcinoma with enteroblastic differentiation complicated by portal vein tumor thrombus
Gastric adenocarcinoma with enteroblastic differentiation (GAED) is an extremely rare gastric cancer subtype with high rates of vascular and lymphatic invasion, lymph node and liver metastasis, leading to poor prognosis and early recurrence. We report a 73-year-old woman with stage IV GAED and portal vein tumor thrombus (PVTT) treated with multimodal therapy. She received S-1 plus oxaliplatin (SOX), SOX plus nivolumab, S-1 plus nivolumab, and radiotherapy for PVTT without major adverse events. Imaging showed marked tumor and lymph node shrinkage and complete PVTT disappearance. Laparoscopic distal gastrectomy with D2 dissection achieved R0 resection; pathology confirmed GAED, ypT2N1M0, Stage IIA, with Grade 1b response. This case suggests SOX plus nivolumab is effective for advanced GAED and that radiotherapy for PVTT enables curative surgery. Preoperative chemoradiotherapy and conversion surgery may provide a promising strategy for otherwise unresectable GAED.
- 26 July 2026
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 19 (5) , 1126-1132
Multimodal approach enables R0 resection in advanced gastric adenocarcinoma with enteroblastic differentiation complicated by portal vein tumor thrombus
Gastric adenocarcinoma with enteroblastic differentiation (GAED) is an extremely rare gastric cancer subtype with high rates of vascular and lymphatic invasion, lymph node and liver metastasis, leading to poor prognosis and early recurrence. We report a 73-year-old woman with stage IV GAED and portal vein tumor thrombus (PVTT) treated with multimodal therapy. She received S-1 plus oxaliplatin (SOX), SOX plus nivolumab, S-1 plus nivolumab, and radiotherapy for PVTT without major adverse events. Imaging showed marked tumor and lymph node shrinkage and complete PVTT disappearance. Laparoscopic distal gastrectomy with D2 dissection achieved R0 resection; pathology confirmed GAED, ypT2N1M0, Stage IIA, with Grade 1b response. This case suggests SOX plus nivolumab is effective for advanced GAED and that radiotherapy for PVTT enables curative surgery. Preoperative chemoradiotherapy and conversion surgery may provide a promising strategy for otherwise unresectable GAED.
- 27 March 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (4) , 2211-2221
Delayed Initiation of Postoperative S-1 Adjuvant Chemotherapy Worsens Prognosis After Gastric Cancer Recurrence
Previous reports revealed the negative prognostic factors for patients with gastric cancer (GC) who received curative surgery plus postoperative S-1 chemotherapy. However, there were few reports on the survival time of patients after the recurrence of GC. Therefore, this study aimed to investigate overall survival (OS) after the recurrence of GC in patients who received postoperative S-1 chemotherapy. We retrospectively analyzed 44 consecutive patients with Stage II-III GC who received postoperative S-1 chemotherapy between 2013 and 2017 but relapsed. The S-1 initiation time (p=0.002). Multivariate analysis using the Cox proportional hazard model revealed that the S-1 initiation time (≤50 days) was independent poor prognostic factor for OS after recurrence (p=0.017). Logistic regression analysis revealed that postoperative prognostic nutritional index (PNI) (p=0.002) and postoperative complications (p=0.014) were independent risk factors for the proper initiation time. OS after recurrence was extended by initiating the postoperative chemotherapy within 50 days. Postoperative nutritional management and reduction of postoperative complications may prevent a delay in the initiation of postoperative S-1 chemotherapy and improve the prognosis.
- 27 March 2026
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 46 (4) , 2211-2221
Delayed Initiation of Postoperative S-1 Adjuvant Chemotherapy Worsens Prognosis After Gastric Cancer Recurrence
Previous reports revealed the negative prognostic factors for patients with gastric cancer (GC) who received curative surgery plus postoperative S-1 chemotherapy. However, there were few reports on the survival time of patients after the recurrence of GC. Therefore, this study aimed to investigate overall survival (OS) after the recurrence of GC in patients who received postoperative S-1 chemotherapy. We retrospectively analyzed 44 consecutive patients with Stage II-III GC who received postoperative S-1 chemotherapy between 2013 and 2017 but relapsed. The S-1 initiation time (p=0.002). Multivariate analysis using the Cox proportional hazard model revealed that the S-1 initiation time (≤50 days) was independent poor prognostic factor for OS after recurrence (p=0.017). Logistic regression analysis revealed that postoperative prognostic nutritional index (PNI) (p=0.002) and postoperative complications (p=0.014) were independent risk factors for the proper initiation time. OS after recurrence was extended by initiating the postoperative chemotherapy within 50 days. Postoperative nutritional management and reduction of postoperative complications may prevent a delay in the initiation of postoperative S-1 chemotherapy and improve the prognosis.
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0440
Desmoid-Type Fibromatosis of the Proximal Jejunum Mimicking Gastric Gastrointestinal Stromal Tumor: Diagnostic Pitfalls in Determining the Tumor Origin
INTRODUCTION: Desmoid-type fibromatosis (DTF) of the small intestine is rare and often mimics gastrointestinal stromal tumor (GIST). Its infiltrative growth can also make identification of the true organ of origin difficult.CASE PRESENTATION: A 56-year-old woman was referred with a suspected gastric GIST based on imaging and endoscopic US-guided fine-needle aspiration. Before the planned surgery, the patient developed anorexia and vomiting. Emergency CT revealed rapid tumor enlargement with duodenal obstruction. Urgent multi-organ resection was performed, including partial gastrectomy, jejunal resection, partial pancreatic resection, and partial colectomy. Intraoperatively, the tumor appeared to originate from the stomach; however, histopathological examination revealed DTF arising from the jejunum with secondary invasion into adjacent organs. The postoperative course was complicated by an intra-abdominal abscess, which was successfully managed. No recurrence was observed 12 months after surgery.CONCLUSIONS: DTF should be considered in rapidly enlarging peri-gastrointestinal tumors with bowel obstruction. This case highlights the difficulty not only in differentiating DTF from GIST but also in accurately identifying the organ of origin.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0440
Open AccessDesmoid-Type Fibromatosis of the Proximal Jejunum Mimicking Gastric Gastrointestinal Stromal Tumor: Diagnostic Pitfalls in Determining the Tumor Origin
INTRODUCTION: Desmoid-type fibromatosis (DTF) of the small intestine is rare and often mimics gastrointestinal stromal tumor (GIST). Its infiltrative growth can also make identification of the true organ of origin difficult.CASE PRESENTATION: A 56-year-old woman was referred with a suspected gastric GIST based on imaging and endoscopic US-guided fine-needle aspiration. Before the planned surgery, the patient developed anorexia and vomiting. Emergency CT revealed rapid tumor enlargement with duodenal obstruction. Urgent multi-organ resection was performed, including partial gastrectomy, jejunal resection, partial pancreatic resection, and partial colectomy. Intraoperatively, the tumor appeared to originate from the stomach; however, histopathological examination revealed DTF arising from the jejunum with secondary invasion into adjacent organs. The postoperative course was complicated by an intra-abdominal abscess, which was successfully managed. No recurrence was observed 12 months after surgery.CONCLUSIONS: DTF should be considered in rapidly enlarging peri-gastrointestinal tumors with bowel obstruction. This case highlights the difficulty not only in differentiating DTF from GIST but also in accurately identifying the organ of origin.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gastric Cancer
- Vol. 26 (2) , 232-246
Endoscopic Features of Background Gastritis Associated With Remnant Gastric Cancer: A Multicenter Retrospective Study
Ohashi T, et al. J Gastric Cancer. 2026 Apr;26(2):232-246. https://doi.org/10.5230/jgc.2026.26.e15
- 1 January 2026
- Published by XMLink in Journal of Gastric Cancer
- Vol. 26 (2) , 232-246
Open AccessEndoscopic Features of Background Gastritis Associated With Remnant Gastric Cancer: A Multicenter Retrospective Study
Ohashi T, et al. J Gastric Cancer. 2026 Apr;26(2):232-246. https://doi.org/10.5230/jgc.2026.26.e15
- Open Access
- 15 May 2023
- Published by Wiley in Cancer Science
- Vol. 114 (7) , 3027-3040
Plasma miR‐1254 as a predictive biomarker of chemosensitivity and a target of nucleic acid therapy in esophageal cancer
This study investigated novel tumor suppressor microRNAs (miRNAs) that decrease in plasma and predict chemosensitivity to neoadjuvant chemotherapy (NAC) for esophageal squamous cell carcinoma (ESCC) and revealed their usefulness as novel therapeutic agents. We selected four miRNA candidates (miR-323, 345, 409, and 1254) based on the microRNA microarray comparing pre-treatment plasma levels in ESCC patients with high and low histopathological responses to NAC and an NCBI database review. Among these miRNA candidates, miR-1254 was more highly elevated in pre-treatment plasma of ESCC patients with a high histopathological response than in those with a low histopathological response (P = 0.0021, area under the receiver-operating characteristic curve 0.7621). High plasma miR-1254 levels tended to correlate with the absence of venous invasion (P = 0.0710) and were an independent factor predicting a higher response to chemotherapy (P = 0.0022, odds ratio 7.86) and better prognosis (P = 0.0235, hazard ratio 0.23). Overexpressing miR-1254 in ESCC cells significantly enhanced chemosensitivity to cisplatin through the transcriptional regulation of ABCC1 in vitro. Moreover, increased plasma miR-1254 levels by subcutaneous injection significantly improved responses to cisplatin in mice. Plasma miR-1254 might be a useful biomarker for predicting responses to NAC, and the restoration of plasma miR-1254 levels might improve chemosensitivity in ESCC.
- 15 May 2023
- Published by Wiley in Cancer Science
- Vol. 114 (7) , 3027-3040
Open AccessPlasma miR‐1254 as a predictive biomarker of chemosensitivity and a target of nucleic acid therapy in esophageal cancer
This study investigated novel tumor suppressor microRNAs (miRNAs) that decrease in plasma and predict chemosensitivity to neoadjuvant chemotherapy (NAC) for esophageal squamous cell carcinoma (ESCC) and revealed their usefulness as novel therapeutic agents. We selected four miRNA candidates (miR-323, 345, 409, and 1254) based on the microRNA microarray comparing pre-treatment plasma levels in ESCC patients with high and low histopathological responses to NAC and an NCBI database review. Among these miRNA candidates, miR-1254 was more highly elevated in pre-treatment plasma of ESCC patients with a high histopathological response than in those with a low histopathological response (P = 0.0021, area under the receiver-operating characteristic curve 0.7621). High plasma miR-1254 levels tended to correlate with the absence of venous invasion (P = 0.0710) and were an independent factor predicting a higher response to chemotherapy (P = 0.0022, odds ratio 7.86) and better prognosis (P = 0.0235, hazard ratio 0.23). Overexpressing miR-1254 in ESCC cells significantly enhanced chemosensitivity to cisplatin through the transcriptional regulation of ABCC1 in vitro. Moreover, increased plasma miR-1254 levels by subcutaneous injection significantly improved responses to cisplatin in mice. Plasma miR-1254 might be a useful biomarker for predicting responses to NAC, and the restoration of plasma miR-1254 levels might improve chemosensitivity in ESCC.
- 6 September 2022
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 407 (8) , 3413-3421
Dismal prognosis of elderly gastric cancer patients who underwent gastrectomy with American Society of Anesthesiologists (ASA) 3
Background Although the American Society of Anesthesiologists (ASA) score of 3 is relatively common in elderly patients, there have been few debates on the indications for gastrectomy in elderly gastric cancer (GC) patients with ASA3. Therefore, this study aimed to investigate gastrectomy’s clinical relevance in elderly patients with GC and ASA3. Methods We retrospectively analyzed 228 consecutive elderly GC patients (aged ≥ 75 years) without prior treatments who underwent curative gastrectomy between 2013 and 2017. Results Thirty-three patients with ASA3 showed significantly poorer prognosis than those with ASA1 and 2 (p = 0.004). The multivariate Cox proportional hazards model showed that ASA3 (p = 0.021) and pStage (p = 0.007) were independent prognostic factors, respectively. Elderly GC patients with pStage III and ASA3 exhibited uniquely dismal prognosis (p < 0.001); however, several survivors were still confirmed. Postoperative complications (PCs) were only the final remnant independent prognostic factor (p = 0.020) among the 33 elderly GC patients with ASA3, where dead patients included cancer-specific and other deaths, especially pneumonia. PCs were independently associated with prognostic nutritional index (PNI) (< 42.7) in elderly GC patients, and the most frequent complication was pneumonia, which was significantly associated with ASA3 and marginally associated with PNI in a multivariate analysis. Conclusions ASA3 has a dismal prognosis after curative gastrectomy in the elderly GC patients, but the number of survivors was confirmed. Curative gastrectomy is not considered contraindicated even in elderly GC with ASA3. Preoperative malnutrition is associated with PCs, which proposing preoperative nutritional intervention in the context of treatment strategy for the elderly GC patients with ASA3.
- 6 September 2022
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 407 (8) , 3413-3421
Dismal prognosis of elderly gastric cancer patients who underwent gastrectomy with American Society of Anesthesiologists (ASA) 3
Background Although the American Society of Anesthesiologists (ASA) score of 3 is relatively common in elderly patients, there have been few debates on the indications for gastrectomy in elderly gastric cancer (GC) patients with ASA3. Therefore, this study aimed to investigate gastrectomy’s clinical relevance in elderly patients with GC and ASA3. Methods We retrospectively analyzed 228 consecutive elderly GC patients (aged ≥ 75 years) without prior treatments who underwent curative gastrectomy between 2013 and 2017. Results Thirty-three patients with ASA3 showed significantly poorer prognosis than those with ASA1 and 2 (p = 0.004). The multivariate Cox proportional hazards model showed that ASA3 (p = 0.021) and pStage (p = 0.007) were independent prognostic factors, respectively. Elderly GC patients with pStage III and ASA3 exhibited uniquely dismal prognosis (p < 0.001); however, several survivors were still confirmed. Postoperative complications (PCs) were only the final remnant independent prognostic factor (p = 0.020) among the 33 elderly GC patients with ASA3, where dead patients included cancer-specific and other deaths, especially pneumonia. PCs were independently associated with prognostic nutritional index (PNI) (< 42.7) in elderly GC patients, and the most frequent complication was pneumonia, which was significantly associated with ASA3 and marginally associated with PNI in a multivariate analysis. Conclusions ASA3 has a dismal prognosis after curative gastrectomy in the elderly GC patients, but the number of survivors was confirmed. Curative gastrectomy is not considered contraindicated even in elderly GC with ASA3. Preoperative malnutrition is associated with PCs, which proposing preoperative nutritional intervention in the context of treatment strategy for the elderly GC patients with ASA3.
- 20 January 2022
- Published by Springer Nature in Surgery Today
- Vol. 52 (8) , 1218-1228
Short- and long-term outcomes of laparoscopic distal gastrectomy versus open distal gastrectomy for gastric cancer in overweight patients
Purpose and background Gastrectomy for gastric cancer in overweight patients is associated with a high incidence of postoperative complications and difficulties in achieving adequate lymph node dissection. We conducted this study to compare the outcomes of laparoscopic and open distal gastrectomy (ODG) for gastric cancer in overweight Japanese patients. Methods This retrospective study analyzed data from 180 patients with a body mass index ≥ 25 who underwent distal gastrectomy for pStage I–III gastric cancer. Postoperative complications, the number of harvested lymph nodes, and long-term survival were compared between ODG and laparoscopic distal gastrectomy (LDG). Results Postoperative complications of Clavien–Dindo (CD) grade ≥ 2 and ≥ 3 were significantly higher after ODG than after LDG (p < 0.001 and p = 0.004). Multivariate analysis identified age and ODG as factors related to complications of CD ≥ 2 (p = 0.014 and 0.002). The number of harvested lymph nodes at region 4sb was significantly higher in LDG for patients with pStage III disease. The 5-year lymph node recurrence-free survival tended to be better in LDG; however, no difference was found between ODG and LDG at any pathological stage. There were no significant differences in the 5-year overall and recurrence-free survival rates after ODG vs. LDG. Conclusions LDG for gastric cancer appears to be associated with a lower incidence of postoperative complications than ODG, without compromising long-term survival, even for overweight patients.
- 20 January 2022
- Published by Springer Nature in Surgery Today
- Vol. 52 (8) , 1218-1228
Short- and long-term outcomes of laparoscopic distal gastrectomy versus open distal gastrectomy for gastric cancer in overweight patients
Purpose and background Gastrectomy for gastric cancer in overweight patients is associated with a high incidence of postoperative complications and difficulties in achieving adequate lymph node dissection. We conducted this study to compare the outcomes of laparoscopic and open distal gastrectomy (ODG) for gastric cancer in overweight Japanese patients. Methods This retrospective study analyzed data from 180 patients with a body mass index ≥ 25 who underwent distal gastrectomy for pStage I–III gastric cancer. Postoperative complications, the number of harvested lymph nodes, and long-term survival were compared between ODG and laparoscopic distal gastrectomy (LDG). Results Postoperative complications of Clavien–Dindo (CD) grade ≥ 2 and ≥ 3 were significantly higher after ODG than after LDG (p < 0.001 and p = 0.004). Multivariate analysis identified age and ODG as factors related to complications of CD ≥ 2 (p = 0.014 and 0.002). The number of harvested lymph nodes at region 4sb was significantly higher in LDG for patients with pStage III disease. The 5-year lymph node recurrence-free survival tended to be better in LDG; however, no difference was found between ODG and LDG at any pathological stage. There were no significant differences in the 5-year overall and recurrence-free survival rates after ODG vs. LDG. Conclusions LDG for gastric cancer appears to be associated with a lower incidence of postoperative complications than ODG, without compromising long-term survival, even for overweight patients.
- Open Access
- 4 January 2019
- Published by Springer Nature in Molecular Cancer
- Vol. 18 (1) , 2
Low levels of tumour suppressor miR-655 in plasma contribute to lymphatic progression and poor outcomes in oesophageal squamous cell carcinoma
Recent studies identified that low levels of tumour suppressor microRNAs (miRNAs) in plasma/serum relate to tumour progression and poor outcomes in cancers. We selected six candidates (miR-126, 133b, 143, 203, 338-3p, 655) of tumour suppressor miRNAs in oesophageal squamous cell carcinoma (ESCC) by a systematic review of NCBI database. Of these, miR-655 levels were significantly down-regulated in plasma of ESCC patients compared to healthy volunteers by test- and validation-scale analyses. Low levels of plasma miR-655 were significantly associated with lymphatic invasion, lymph node metastasis and advanced stage. Univariate and multivariate analysis revealed that the low level of plasma miR-655 was an independent risk factor of lymphatic progression and a poor prognostic factor. Overexpression of miR-655 in ESCC cells inhibited cell proliferation, migration, invasion and epithelial-mesenchymal transition. Increased plasma miR-655 levels by the subcutaneous injection significantly inhibited lymph node metastasis in mice. Low levels of miR-655 in plasma relate to lymphatic progression and poor outcomes, and the restoration of the plasma miR-655 levels might inhibit tumour and lymphatic progression in ESCC.
- 4 January 2019
- Published by Springer Nature in Molecular Cancer
- Vol. 18 (1) , 2
Open AccessLow levels of tumour suppressor miR-655 in plasma contribute to lymphatic progression and poor outcomes in oesophageal squamous cell carcinoma
Recent studies identified that low levels of tumour suppressor microRNAs (miRNAs) in plasma/serum relate to tumour progression and poor outcomes in cancers. We selected six candidates (miR-126, 133b, 143, 203, 338-3p, 655) of tumour suppressor miRNAs in oesophageal squamous cell carcinoma (ESCC) by a systematic review of NCBI database. Of these, miR-655 levels were significantly down-regulated in plasma of ESCC patients compared to healthy volunteers by test- and validation-scale analyses. Low levels of plasma miR-655 were significantly associated with lymphatic invasion, lymph node metastasis and advanced stage. Univariate and multivariate analysis revealed that the low level of plasma miR-655 was an independent risk factor of lymphatic progression and a poor prognostic factor. Overexpression of miR-655 in ESCC cells inhibited cell proliferation, migration, invasion and epithelial-mesenchymal transition. Increased plasma miR-655 levels by the subcutaneous injection significantly inhibited lymph node metastasis in mice. Low levels of miR-655 in plasma relate to lymphatic progression and poor outcomes, and the restoration of the plasma miR-655 levels might inhibit tumour and lymphatic progression in ESCC.